Modulators of development of adipocyte and cancer cells

Patent metadata

Field	Value
Publication number	US-10029991-B2
Application number	US-201313953013-A
Country	US
Kind code	B2
Filing date	Jul 29, 2013
Priority date	Jan 27, 2011
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.

First claim

The invention claimed is:

1. A method of treating obesity in a subject comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a first compound selected from the group consisting of COH-SR1, COH-SR2, COH-SR6, COH-SR7, COH-SR11, LR59:
and the pharmaceutically acceptable salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. The method according to claim 1 , wherein the first compound is selected from the group consisting of COH-SR1, COH-SR2, COH-SR7, LR59, and the pharmaceutically acceptable salts and stereoisomers thereof, including mixtures thereof in all ratios.

3. A method of treating a cancer selected from the group consisting of leukemia, acute myeloid leukemia (AML), monocytic leukemia, lung cancer, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, brain cancer and breast cancer in a subject comprising administering to the subject a first pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a first compound selected from the group consisting of COH-SR2, COH-SR6, COH-SR7,
and the pharmaceutically acceptable salts and stereoisomers thereof, including mixtures thereof in all ratios.

4. The method according to claim 3 , wherein the pharmaceutical composition further comprising a second therapeutic agent selected from the group consisting of TMZ, SN38, CPT-11, and 5-FU.

5. The method according to claim 3 , further comprising administering a second pharmaceutical composition comprising a second therapeutic agent.

6. The method according to claim 5 , wherein the second therapeutic agent selected from the group consisting of TMZ, SN38, CPT-11, 5-FU and anti-RLIP76 IgG (immunoglobulin).

Assignees

• Hope City

Inventors

• Rahbar Samuel
• Figarola James L
• Lincoln Christopher
• Horne David
• Mooney Rachael
• Polewski Monika
• Somlo George
• Yang Lixin
• Awasthi Sanjay

Classifications

• C07C2601/14

  The ring being saturated · CPC title

• C07D229/00

  Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms · CPC title

• A61K31/197

  the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205) · CPC title

• C07D213/75

  Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates · CPC title

• C07C275/34

  having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring · CPC title